Here are the 424B prospectus supplements from ADC Therapeutics SA (ADCT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
ADC Therapeutics SA updates its prospectus to confirm that 27,726,052 common shares remain registered for resale by selling shareholders under the prospectus dated July 9, 2025. The supplement dated April 15, 2026 registers a transfer of 1,383,144 shares from Point72 Associates, LLC to SILV Fund Ltd., reducing Point72’s offering by that amount and adding SILV Fund Ltd. as a selling shareholder; the aggregate registered amount is unchanged.
ADC Therapeutics files a resale prospectus to register 9,834,776 common shares issuable upon exercise of warrants issued to HCR on February 18, 2026. The selling shareholders may offer up to 9,834,776 shares from time to time at market, different or private prices. The company states we are not selling any common shares included in this prospectus and will not receive any of the proceeds from such resale; however, if the warrants are exercised for cash the company may receive up to $37.5 million to be used for working capital and general corporate purposes.